Comera Life Sciences Holdings, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Comera Life Sciences Holdings, Inc. Comera Life Sciences Holdings, Inc. (CMRA) is a preclinical-stage biotechnology company that develops proprietary therapeutics using its SQore formulation platform to convert intravenous biologics into subcutaneous versions; core products include CLS-001, a subcutaneous formulation of vedolizumab for inflammatory bowel disease such as Crohn's disease and ulcerative colitis, CM-01, a subcutaneous version of adalimumab, and CMRA-CD401, an anti-CD40L therapeutic antibody for solid tumors; the SQore platform integrates computational modeling, proprietary excipients like caffeine to reduce viscosity, and advanced formulation engineering for monoclonal antibodies and other biologics. Founded in 2014 and headquartered in Woburn, Massachusetts, the company targets biopharmaceutical firms and patients requiring improved drug delivery, with operations focused on the United States and strategic collaborations extending globally. Recent developments encompass a 2024 bridge financing round with warrant exercises for capital infusion, ongoing exploration of strategic alternatives including potential mergers, acquisitions, or licensing since late 2023, expanded intellectual property portfolio with new U.S. patents for SQore excipients, and research partnerships such as with Intas Pharmaceuticals in 2022 and a top-10 pharmaceutical company for subcutaneous formulations, alongside collaborations like Quality Chemical Laboratories for supply chain support.
Actinium Pharmaceuticals (NYSE:ATNM) vs. Comera Life Sciences (NASDAQ:CMRA) Critical Comparison
Critical Contrast: Palatin Technologies (PINK:PTNT) vs. Comera Life Sciences (NASDAQ:CMRA)
Reviewing Comera Life Sciences (NASDAQ:CMRA) & Zymeworks (NYSE:ZYME)
Comera Life Sciences Announces Bridge Financing and Exercise of Take Private Option
Comera Life Sciences Announces Process Exploring Strategic Alternatives
Comera Life Sciences Appoints Dorothy Clarke to Board of Directors
Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights
Comera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery Conference
These Are the ONLY 7 Penny Stocks to Consider in August 2023
Comera Life Sciences Announces Publication of Study Reinforcing Caffeine's Viscosity Reducing Capabilities
Comera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business Highlights
Comera Life Sciences Significantly Expands Intellectual Property Portfolio Strengthening the Proprietary SQore™ Platform
Comera Life Sciences Announces Collaboration with Quality Chemical Laboratories to Secure Proprietary Supply of SQore Excipients
Comera Life Sciences to Present at 22nd Annual PepTalk Conference
Comera Life Sciences to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference
3 Hot Penny Stocks To Buy According To Insiders In September
Top Penny Stocks to Watch After the Market Crash
Insiders Are Buying Up Comera Life Sciences (CMRA) Stock. Here's Why.
Best Penny Stocks To Buy As Recession Begins? 5 Biotech Stocks To Watch
Best Penny Stocks To Buy? 4 To Watch After PGY Stock Explodes 790%